Atara Biotherapeutics (ATRA) Set to Post Quarterly Earnings on Wednesday

Atara Biotherapeutics (NASDAQ:ATRA) is anticipated to announce its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect Atara Biotherapeutics to post earnings of ($0.1328) per share and revenue of $0.80 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:00 PM ET.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported ($0.32) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.32). The company had revenue of $0.63 million for the quarter, compared to the consensus estimate of $0.55 million. On average, analysts expect Atara Biotherapeutics to post ($0.22) EPS for the current fiscal year and $1.38 EPS for the next fiscal year.

Atara Biotherapeutics Price Performance

ATRA opened at $8.25 on Wednesday. The business’s 50-day moving average is $9.15 and its two-hundred day moving average is $7.71. Atara Biotherapeutics has a 1 year low of $3.92 and a 1 year high of $19.15. The firm has a market capitalization of $82.83 million, a PE ratio of -6.99 and a beta of 0.28.

Insider Activity

In other Atara Biotherapeutics news, CEO Anhco Nguyen sold 5,062 shares of the firm’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $8.08, for a total value of $40,900.96. Following the completion of the sale, the chief executive officer owned 132,775 shares of the company’s stock, valued at approximately $1,072,822. This trade represents a 3.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Brian Cherry purchased 104,166 shares of the company’s stock in a transaction dated Friday, September 4th. The shares were acquired at an average price of $9.60 per share, for a total transaction of $999,993.60. Following the purchase, the director directly owned 166,486 shares of the company’s stock, valued at approximately $1,598,265.60. The trade was a 167.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 41.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several analysts have commented on the stock. Wall Street Zen raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, August 16th. TD Cowen upgraded shares of Atara Biotherapeutics to a “strong-buy” rating in a report on Monday, August 24th. Finally, Weiss Ratings raised shares of Atara Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $9.50.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics is a biopharmaceutical company focused on developing allogeneic T-cell immunotherapies for cancer and serious diseases associated with Epstein-Barr virus (EBV). The company’s platform uses donor-derived, virus-specific T cells that are designed to recognize and eliminate infected or malignant cells without requiring cells to be collected from each individual patient.

Atara’s lead product, tabelecleucel, is marketed in the European Union under the brand name Ebvallo.